Open AccessItolizumab in psoriasis
Author(s) -
Ankita Srivastava
Publication year - 2017
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_467_16
Subject(s) - medicine , psoriasis , adverse effect , monoclonal antibody , dermatology , scavenger receptor , pharmacology , immune system , monoclonal , antibody , immunology , lipoprotein , cholesterol
A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored.